News Releases

Year

Aug 05, 2019

UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019

Conference Call and Webcast Scheduled for Monday, August 12, 2019 at 8:30 AM ET NEW YORK --(BUSINESS WIRE)--Aug. 5, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report second quarter 2019 financial results on Friday, August 9, 2019 , prior to the open of the market.

Jul 01, 2019

UroGen Pharma Joins Russell 3000® Index

NEW YORK --(BUSINESS WIRE)--Jul. 1, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it joined the broad-market Russell 3000 ® Index at the conclusion of the 2019 Russell indexes

May 30, 2019

UroGen Pharma to Present at June 2019 Investor Conferences

NEW YORK --(BUSINESS WIRE)--May 30, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at three investor conferences in June: Jefferies 2019 Global Healthcare Conference Tuesday, June 4th 9:00AM Eastern Time New York, NY Goldman Sachs 40 th Annual Global

May 09, 2019

UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments

Recent Data Presentation Highlights Consistent Complete Response Rate and Strong Durability at Six-Months in Evaluable Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Completion of UGN-101 Rolling NDA Submission to the FDA On Track for 2H 2019 Pre-Commercial Activities and

May 05, 2019

UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial

Complete Response (CR) Rate Consistent at 59 Percent Six-month Durability Strong with 89 Percent of Evaluable Patients Remaining in CR Full Phase 3 Data Anticipated for 2H 2019 NEW YORK --(BUSINESS WIRE)--May 5, 2019-- UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company

May 02, 2019

UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

Conference Call and Webcast Scheduled for 8:30 AM ET NEW YORK --(BUSINESS WIRE)--May 2, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019 , prior to the open of the market.

Apr 23, 2019

UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen

Focused Agreement is on Therapeutic Area of Mutual Interest NEW YORK --(BUSINESS WIRE)--Apr. 23, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an

Apr 05, 2019

UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer

NEW YORK --(BUSINESS WIRE)--Apr. 5, 2019-- UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced a new presentation from the pivotal Phase 3 OLYMPUS trial of UGN-101 (mitomycin gel) for

Mar 05, 2019

UroGen Pharma to Present at March 2019 Investor Conferences

NEW YORK --(BUSINESS WIRE)--Mar. 5, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March: Cowen and Company 39 th Annual Health Care Conference Tuesday, March 12 th 11:20AM Eastern Time Boston, MA Oppenheimer 29 th Annual

Feb 28, 2019

UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results

On Track to Complete UGN-101 Rolling NDA Submission to the FDA in 2H 2019 Acceleration of Pre-Commercial Activities and Infrastructure Buildout Underway to Support the Potential U.S. Approval and Launch of UGN-101 in 1H 2020 Initial Data from UGN-102 Trial Anticipated in 2019 Conference Call and

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on